Dr. Congping Xie – Intellectual Property and Legal Director
Dr. Xie has over 25 years of biomedical research and intellectual property management experience in the biopharmaceutical industry. He obtained his M.D. from Hubei Medical University (1984), M.S. in Microbiology and Immunology from Tongji Medical University (1988), and J.D. from Indiana University School of Law (2008).
Dr. Xie served as a Postdoctoral Research Fellow in Immunology at the Mayo Clinic from 1991 to 1994, where he characterised T-cell repertoires in rheumatoid arthritis and identified a novel human B-cell subset. He subsequently worked at Indiana University from 1994 to 1998, developing transgenic mouse models and managing laboratory research. Dr. Xie joined Eli Lilly and Company as a biologist in 1998 and served as a Patent Agent and Patent Research Consultant within Lilly IP Legal from 2003 to 2026. During his tenure, he developed patent and lifecycle strategies for antibodies, bispecific and multispecific antibodies, antibody-drug conjugates, formulations and combination therapies, and conducted freedom-to-operate analyses and intellectual property due diligence for licensing and M&A transactions. He also contributed to IP strategies for AI-enabled antibody discovery and next-generation ADC platforms. Dr. Xie is a USPTO-registered patent agent and a member of the Indiana State Bar.